印度毛癣菌感染的临床病程、抗真菌药敏及基因组测序
这项纽约市回顾性队列研究纳入11例印度毛癣菌感染患者,多数有孟加拉国旅行史,均出现广泛皮损、外用抗真菌药单药治疗失败和诊断延迟。7例标准剂量特比萘芬治疗失败者携带角鲨烯环氧化酶L393S或F397L替换,且最低抑菌浓度≥0.5 μg/mL;伊曲康唑治疗7例中5例清除或改善。
要点
- 印度毛癣菌感染常表现为广泛皮损且对标准剂量特比萘芬耐药。
- 角鲨烯环氧化酶L393S或F397L替换与特比萘芬最低抑菌浓度≥0.5 μg/mL相关。
- 伊曲康唑治疗多数有效,氟康唑和灰黄霉素疗效有限。
核心结论
- 印度毛癣菌感染患者常见疾病严重、诊断延迟及对常用剂量和疗程抗真菌药无反应,伊曲康唑通常有效,感染可能获自孟加拉国。
研究设计与样本
- 回顾性队列研究,2022年5月至2023年5月在纽约市6家医疗中心招募11例确诊印度毛癣菌感染患者。
主要发现
- 11例患者中9例有孟加拉国旅行史,所有患者均有广泛皮损、外用抗真菌药单药治疗失败和诊断延迟(范围3-42个月)。
- 7例标准剂量特比萘芬(250 mg每日)长疗程治疗失败,其分离株角鲨烯环氧化酶第393位(L393S)或第397位(F397L)氨基酸替换与特比萘芬最低抑菌浓度≥0.5 μg/mL相关。
- 氟康唑治疗4例中2例改善,灰黄霉素治疗5例中2例改善,疗效与抗真菌最低抑菌浓度无相关性。
- 伊曲康唑治疗7例中5例清除或改善,2例失访或停止治疗。
- 全基因组测序分析显示美国分离株形成与印度分离株不同的聚类。
关键数值与推荐
- 特比萘芬标准剂量为250 mg每日;特比萘芬最低抑菌浓度≥0.5 μg/mL对应角鲨烯环氧化酶L393S或F397L替换。
临床怎么用
- 对广泛皮损且外用抗真菌药失败的患者应怀疑印度毛癣菌感染,并考虑进行菌种鉴定和药敏检测。
- 标准剂量特比萘芬治疗失败时,伊曲康唑可作为治疗选择。
- 详细询问旅行史(如孟加拉国)有助于提示诊断。
局限性
- 回顾性研究、样本量小(11例),部分患者失访或停止治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Trichophyton indotineae is an emerging dermatophyte causing outbreaks of extensive tinea infections often unresponsive to terbinafine. This species has been detected worldwide and in multiple US states, yet detailed US data on infections with T indotineae are sparse and could improve treatment practices and medical understanding of transmission. OBJECTIVE: To correlate clinical features of T indotineae infections with in vitro antifungal susceptibility testing results, squalene epoxidase gene sequence variations, and isolate relatedness using whole-genome sequencing. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study of patients with T indotineae infections in New York City spanned May 2022 to May 2023. Patients with confirmed T indotineae infections were recruited from 6 New York City medical centers. MAIN OUTCOME AND MEASURE: Improvement or resolution at the last follow-up assessment. RESULTS: Among 11 patients with T indotineae (6 male and 5 female patients; median [range] age, 39 [10-65] years), 2 were pregnant; 1 had lymphoma; and the remainder were immunocompetent. Nine patients reported previous travel to Bangladesh. All had widespread lesions with variable scale and inflammation, topical antifungal monotherapy failure, and diagnostic delays (range, 3-42 months). Terbinafine treatment failed in 7 patients at standard doses (250 mg daily) for prolonged duration; these patients also had isolates with amino acid substitutions at positions 393 (L393S) or 397 (F397L) in squalene epoxidase that correlated with elevated terbinafine minimum inhibitory concentrations of 0.5 μg/mL or higher. Patients who were treated with fluconazole and griseofulvin improved in 2 of 4 and 2 of 5 instances, respectively, without correlation between outcomes and antifungal minimum inhibitory concentrations. Furthermore, 5 of 7 patients treated with itraconazole cleared or had improvement at the last follow-up, and 2 of 7 were lost to follow-up or stopped treatment. Based on whole-genome sequencing analysis, US isolates formed a cluster distinct from Indian isolates. CONCLUSION AND RELEVANCE: The results of this case series suggest that disease severity, diagnostic delays, and lack of response to typically used doses and durations of antifungals for tinea were common in this primarily immunocompetent patient cohort with T indotineae, consistent with published data. Itraconazole was generally effective, and the acquisition of infection was likely in Bangladesh.
引用
- Caplan AS, Todd GC, Zhu Y, et al. Clinical Course, Antifungal Susceptibility, and Genomic Sequencing of Trichophyton indotineae. JAMA Dermatol. 2024. PMID: 38748419. doi:10.1001/jamadermatol.2024.1126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。